C-Difficile-Associated Diarrhea: Positive Results In Phase 2 Trial Of Treatment

Medarex, Inc. (Nasdaq: MEDX) and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile Associated Diarrhea (CDAD) successfully met its primary objective.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on November 7th, 2008